Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Henning Olbrich; Christian D. Sadik; Ralf J. Ludwig; Diamant Thaçi; Katharina Boch

doi:10.3390/biom13040634

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Henning Olbrich^*, Christian D. Sadik, Ralf J. Ludwig, Diamant Thaçi, Katharina Boch

^*Corresponding author for this work

73 Citations (Scopus)

Abstract

Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was approved by the U.S. Food and Drug Administration for prurigo nodularis (PN). Given its relatively good safety profile, effective off-label use of dupilumab has been reported for a multitude of dermatologic diseases and several clinical trials for dermatologic skin conditions are currently ongoing. We conducted a systematic review of applications of dupilumab in dermatology other than AD and PN by searching the databases PubMed/Medline, Scopus, Web of Science and Cochrane Library as well as the clinical trial registry ClinicalTrials.gov. We found several reports for effective treatment of bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome and a variety of other chronic inflammatory skin diseases.

Original language	English
Article number	634
Journal	Biomolecules
Volume	13
Issue number	4
ISSN	2218-273X
DOIs	https://doi.org/10.3390/biom13040634
Publication status	Published - 04.2023

Funding

This work was supported by the Clinician Scientist School Lübeck (CS01-2022), by the Cluster of Excellence Precision Medicine in Chronic Inflammation (DFG EXC 2167) and the Schleswig-Holstein Excellence-Chair Program from the State of Schleswig-Holstein.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Academic Focus: Center for Infection and Inflammation Research (ZIEL)
Centers: Center for Research on Inflammation of the Skin (CRIS)

DFG Research Classification Scheme

2.21-05 Immunology
2.22-19 Dermatology
2.22-22 Clinical Immunology and Allergology

Access to Document

10.3390/biom13040634

Cite this

@article{5e5e98c3f1c0419a84f90281ce6d1179,

title = "Dupilumab in Inflammatory Skin Diseases: A Systematic Review",

abstract = "Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was approved by the U.S. Food and Drug Administration for prurigo nodularis (PN). Given its relatively good safety profile, effective off-label use of dupilumab has been reported for a multitude of dermatologic diseases and several clinical trials for dermatologic skin conditions are currently ongoing. We conducted a systematic review of applications of dupilumab in dermatology other than AD and PN by searching the databases PubMed/Medline, Scopus, Web of Science and Cochrane Library as well as the clinical trial registry ClinicalTrials.gov. We found several reports for effective treatment of bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome and a variety of other chronic inflammatory skin diseases.",

author = "Henning Olbrich and Sadik, \{Christian D.\} and Ludwig, \{Ralf J.\} and Diamant Tha{\c c}i and Katharina Boch",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = apr,

doi = "10.3390/biom13040634",

language = "English",

volume = "13",

journal = "Biomolecules",

issn = "2218-273X",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "4",

}

TY - JOUR

T1 - Dupilumab in Inflammatory Skin Diseases

T2 - A Systematic Review

AU - Olbrich, Henning

AU - Sadik, Christian D.

AU - Ludwig, Ralf J.

AU - Thaçi, Diamant

AU - Boch, Katharina

PY - 2023/4

Y1 - 2023/4

N2 - Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was approved by the U.S. Food and Drug Administration for prurigo nodularis (PN). Given its relatively good safety profile, effective off-label use of dupilumab has been reported for a multitude of dermatologic diseases and several clinical trials for dermatologic skin conditions are currently ongoing. We conducted a systematic review of applications of dupilumab in dermatology other than AD and PN by searching the databases PubMed/Medline, Scopus, Web of Science and Cochrane Library as well as the clinical trial registry ClinicalTrials.gov. We found several reports for effective treatment of bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome and a variety of other chronic inflammatory skin diseases.

AB - Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was approved by the U.S. Food and Drug Administration for prurigo nodularis (PN). Given its relatively good safety profile, effective off-label use of dupilumab has been reported for a multitude of dermatologic diseases and several clinical trials for dermatologic skin conditions are currently ongoing. We conducted a systematic review of applications of dupilumab in dermatology other than AD and PN by searching the databases PubMed/Medline, Scopus, Web of Science and Cochrane Library as well as the clinical trial registry ClinicalTrials.gov. We found several reports for effective treatment of bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome and a variety of other chronic inflammatory skin diseases.

UR - https://www.scopus.com/pages/publications/85156159006

UR - https://www.mendeley.com/catalogue/bcd6ff5f-947d-32a2-b6c2-68d2f8943fa8/

U2 - 10.3390/biom13040634

DO - 10.3390/biom13040634

M3 - Scientific review articles

C2 - 37189381

AN - SCOPUS:85156159006

SN - 2218-273X

VL - 13

JO - Biomolecules

JF - Biomolecules

IS - 4

M1 - 634

ER -

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Abstract

Funding

UN SDGs

Research Areas and Centers

DFG Research Classification Scheme

Access to Document

Other files and links

Fingerprint

CRC 1526, PANTAU: Pathomechanisms of Antibody-mediated Autoimmunity

Cite this

Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Abstract

Funding

UN SDGs

Research Areas and Centers

DFG Research Classification Scheme

Access to Document

Other files and links

Fingerprint

Projects

CRC 1526, PANTAU: Pathomechanisms of Antibody-mediated Autoimmunity

Cite this